Literature DB >> 2864254

Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine.

E Scholz, J Dichgans.   

Abstract

A total of 13 patients with drug-induced psychosis in Parkinson's disease were treated with two non-classical neuroleptics-clozapine and fluperlapine. Patients mainly complained about severe hallucinatory symptoms and different degrees of paranoid delusions. Complete relief was observed in 8 patients, moderate improvement in 3 and no effects in 2. Parkinsonian disability did not increase under neuroleptic medication with clozapine and fluperlapine, but could be ameliorated by additional L-dopa or bromocriptine medication. The non-classical neuroleptics employed are dopamine D2 blocking agents with a preferential binding to mesolimbic, mesocortical and hippocampal D2 receptors and no substantial binding to striatal dopamine receptors. Restricted use of these two neuroleptics is necessitated because of the danger of agranulocytosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2864254     DOI: 10.1007/bf00380972

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Neurol Sci        ISSN: 0175-758X


  20 in total

1.  Mental symptoms in Parkinson's disease during chronic treatment with levodopa.

Authors:  R D Sweet; F H McDowell; J S Feigenson; A W Loranger; H Goodell
Journal:  Neurology       Date:  1976-04       Impact factor: 9.910

2.  Mental phenomena induced by stimulation in the limbic system.

Authors:  E Halgren
Journal:  Hum Neurobiol       Date:  1982

3.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

4.  Pharmacology of fluperlapine compared with clozapine.

Authors:  E Eichenberger
Journal:  Arzneimittelforschung       Date:  1984

5.  Fluperlapine in tardive dyskinesia and parkinsonism.

Authors:  S Korsgaard; U Noring; J Gerlach
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

6.  Pergolide therapy for Parkinson's disease: neurobehavioral changes.

Authors:  Y Stern; R Mayeux; J Ilson; S Fahn; L Cote
Journal:  Neurology       Date:  1984-02       Impact factor: 9.910

7.  [Exogenous psychoses in Parkinson syndrome. Frequency and causal conditions].

Authors:  E Schneider; P A Fischer; P Jacobi; A Grotz
Journal:  Fortschr Neurol Psychiatr       Date:  1984-06       Impact factor: 0.752

8.  Pharmacology of hallucinations induced by long-term drug therapy.

Authors:  C G Goetz; C M Tanner; H L Klawans
Journal:  Am J Psychiatry       Date:  1982-04       Impact factor: 18.112

9.  Clozapine-induced agranulocytosis: a situation report up to August 1976.

Authors:  B Anderman; R W Griffith
Journal:  Eur J Clin Pharmacol       Date:  1977-03-11       Impact factor: 2.953

10.  Agranulocytosis during treatment with chlozapine.

Authors:  J Idänpään-Heikkilä; E Alhava; M Olkinuora; I P Palva
Journal:  Eur J Clin Pharmacol       Date:  1977-03-11       Impact factor: 2.953

View more
  17 in total

1.  Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up.

Authors:  P Pollak; F Tison; O Rascol; A Destée; J J Péré; J M Senard; F Durif; I Bourdeix
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

Review 2.  Do neuroleptic drugs still have a place in neurological therapy?

Authors:  T Klockgether; J Dichgans
Journal:  J Neurol       Date:  1990-07       Impact factor: 4.849

Review 3.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

Review 4.  Parkinson's disease.

Authors:  C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-06       Impact factor: 10.154

5.  A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens.

Authors:  Zhu Li; Junji Ichikawa; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2003-03-28       Impact factor: 4.530

6.  Bromocriptine and psychosis: a literature review.

Authors:  A Boyd
Journal:  Psychiatr Q       Date:  1995

7.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

Review 8.  Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.

Authors:  Shyam C Panchal; William G Ondo
Journal:  Curr Psychiatry Rep       Date:  2018-01-27       Impact factor: 5.285

9.  The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic drug clozapine in rats.

Authors:  Adam J Prus; Alan L Pehrson; Scott D Philibin; Jesse T Wood; Sarah A Vunck; Joseph H Porter
Journal:  Psychopharmacology (Berl)       Date:  2008-08-07       Impact factor: 4.530

10.  Novel Antipsychotics in the Treatment of Behavioral Disturbances and Psychoses Associated With Neurodegenerative Disorders.

Authors:  Prakash S. Masand
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.